Chacruna Institute is a registered California 501(c)(3) non-profit. We are a volunteer-led organization run by a team of experts and enthusiasts who give their time freely to bring education and cultural understanding about psychedelic plant medicines to a wider audience. We promote a bridge between the ceremonial use of sacred plants and psychedelic science and envisage a world where plant medicines and other psychedelics are preserved, protected, and valued as part of our cultural identity and integrated into our social, legal and health care systems. Help us to achieve our mission! Please consider becoming a monthly donor so that your impact spans the entire year. Support of any frequency or amount helps the cause.
To make a donation click the button below:
To register for monthly recurrent donations fill the form below:
In recent times, there has been more advances in medical research on cannabis. Francisco Savoi de Arauja and Mauro Machado Chaiben demystify the modalities that go beyond the medical model. They primarily focus on the political need to decriminalize marijuana, and include references to the religious and social uses of marijuana by Rastafarian culture, Santo Daime religion, and “Cannabis Social Clubs.”
The Indigenous Peyote Conservation Communication Committee wrote a letter to the psychedelic community regarding the inclusion of Peyote in decriminalization measures. This letter provides context, history, and details about Native Americans’ relationship with Peyote, the Native American Church, and NAC’s conservation efforts, and also includes suggestions of how psychedelic and decriminalization movements can be an ally to Native American communities.
Marcelo Leite, Ph.D., summarizes how the medicalization and legalization regulatory models for psilocybin-assisted therapy can “naturally coexist within an integrated framework.” There are advantages and limitations to each model, and as investors begin to invest their attention on the emerging psychedelic therapies and research, it is important for all psychedelic organizations to work in tandem with each other’s framework as it will best serve the movement and public access for psilocybin-assisted therapy.
Jasmine Virdi interviews Martha Hartney, an attorney fighting for the legal use of aya-huasca as a religious sacrament within the United States. In this article, Martha Hart-ney shares about the legal status of ayahuasca, how this intersects with the Religious Freedom Restoration Act (RFRA), and how we can collectively work towards securing the right to drink ayahuasca in bona fide religious settings.
Not-for-profit organizations, like MAPS and Usona Institute, are just a few years away from completing FDA trials to medicalize psychedelic therapy. As psychedelic research gets closer to medicalization, for-profit companies, like COMPASS institute and ATAI Life Sciences, have filed patents about psilocybin, MDMA, and DMT. The author describes how for-profit’s patent claims and capitalism are impacting the psychedelic renaissance -- a movement with origins of psychedelic research in the 1960s, the summer of love, and healing for all.
This article introduces the Hablemos del Hikuri peyote conservation project that began in 2017 to research and put into action peyote conservation within Wixarika communities. Its co-founders, Lisbeth Bonilla and Pedro Nájera present the interdisciplinary and intercultural approach this project has toward finding a solution to peyote’s endangered status.
The Supreme Court’s December 2020 ruling in Tanzin v. Tanvir has several lessons for psychedelic religions, as well as the promise that they have a path to compensation for discrimination at the hand of federal officials. Psychedelics law expert Gary Smith explains the ruling and its potential opportunity for expanded recognition of psychedelic religious liberty.
In the 2020 election, we have witnessed major drug policy reform happen in states like Oregon which has voted in a psilocybin therapy model and broad drug decriminalization. What should Californian constituents consider for the future of psychedelic legislation? Ariel Clark argues that psychedelic legislation should begin with decriminalizing all drugs.